Simvastatin reduces tumor cell adhesion to human peritoneal mesothelial cells by decreased expression of VCAM-1 and $\beta_1$ integrin

BRITTA JANINA WAGNER$^{1,2,5}$, STEFAN LÖB$^{1,2}$, DENNIS LINDAU$^1$, HELEN HÖRZER$^{1,3}$, BRIGITTE GÜCKEL$^3$, GÉRD KLEIN$^4$, JÖRG GLATZLE$^2$, HANS-GEORG RAMMENSEE$^1$, BJÖRN LUCAS DIETRICH MARIA BRÜCHER$^2$ and ALFRED KÖNIGSRAINER$^2$

$^1$Department of Immunology, University of Tübingen, Auf der Morgenstelle 15; $^2$Department of General, Visceral, and Transplantation Surgery, Comprehensive Cancer Center, University of Tübingen, Hoppe-Seyler-Str. 3; $^3$Department of Obstetrics and Gynecology, University of Tübingen, Calwer Str. 7, D-72076 Tübingen; $^4$University Medical Clinic, Center for Medical Research, Section for Transplantation Immunology and Immunohematology, University of Tübingen, Waldhörnlestr. 22, D-72072 Tübingen, Germany

Received June 6, 2011; Accepted July 11, 2011

DOI: 10.3892/ijo.2011.1167

Abstract. Peritoneal carcinomatosis describes cancer metastasis onto the surface of the peritoneum. It is frequently caused by ovarian and colorectal cancer. Once a tumor has penetrated the peritoneum, cancer cells disseminate into the abdominal cavity. Additionally, surgery can account for the spread of free tumor cells. Their subsequent adhesion to mesothelial cells (HMCs) initiates peritoneal carcinomatosis. Therefore, this study analyzed the effect of simvastatin on tumor cell adherence. HMCs were isolated from human greater omentum. Fluorescence-labeled tumor cells (SKOV-3, OvCar-29, OAW42, FraWü; ovarian/HT29; colorectal) were incubated on confluent mesothelial monolayers with 10 $\mu$M simvastatin for 48 h. Adhesion was quantified using a fluorescence reader. Expression of the adhesion molecules VCAM-1, ICAM-1 and $\beta_1$ integrin chain under the influence of simvastatin 0.1-100 $\mu$M for 24-72 h was analyzed using flow cytometry. Simvastatin significantly reduced the adhesion of all ovarian cancer cells and HT29 to HMCs (P≤0.001). Concomitantly simvastatin decreased the expression of VCAM-1 on HMCs and the integrin $\alpha_\beta_1$ on tumor cells. As an example of adhesion molecule down-regulating drugs, simvastatin may provide a novel therapeutic approach to the prevention of peritoneal carcinomatosis.

Introduction

Peritoneal carcinomatosis is associated with a median survival of less than one year and has long been regarded as incurable (1). In contrast to the majority of solid tumors, metastatic spread in ovarian cancer is primarily into the abdominal cavity (2). Approximately three-quarters of ovarian cancer patients are diagnosed in the advanced stages FIGO III, characterized by peritoneal metastases throughout the abdominal cavity, or IV, defined by distant metastases (3). Only 20-25% of patients with advanced stages can be cured (4). Even early-stage ovarian cancer is characterized by peritoneal carcinomatosis in the pelvis (IIb) or by ascites positive for tumor cells (IIc), with a recurrence rate of 40-50% (5).

Despite advances in the early detection of colorectal cancer, peritoneal lavage fluid of colorectal cancer patients obtained prior to resection proved to be positive in 3-28% (6). About one-third of patients with pT3/4 colorectal cancer die of peritoneal carcinomatosis (7). Curative resection of colon and rectal cancer were followed by peritoneal carcinomatosis in 4-12% and 2-19%, respectively (6). The median survival of patients with peritoneal carcinomatosis can be significantly increased by cytoreductive surgery followed by hyperthermic intra-peritoneal chemotherapy (1); however, up to 80% of the patients still experience a recurrence in the first year after surgery (8).

Human mesothelial cells (HMCs) cover the peritoneum (9). The degree of surgical trauma to mesothelial surfaces correlates directly with the rate of tumor recurrence (10,11). Further, exfoliated cancer cells during resection of primary tumors correlated with intra-peritoneal tumor recurrence (12-14). Surgery induces a sterile inflammatory response, which results in up-regulation of adhesion molecules such as intercellular cell adhesion molecule.
(ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 on HMCs (15,16). Ovarian cancer cell adhesion to HMCs is dependent on VCAM-1 (17). VCAM-1-blocking reduced tumor cell adhesion and growth in vitro and in an in vivo mouse model (17). Further, α₅β₃ integrin, a known ligand of VCAM-1, is expressed by ovarian cancer cells and mediates adhesion to HMCs (17,18). Intra-abdominal injection of heparin reduced ICAM-1 expression on HMCs and prevented peritoneal colorectal tumor growth in an in vivo rat model (19). Additionally, colorectal cancer cell adherence to human umbilical vein endothelial cells (HUVECs) is mainly ICAM-1-dependent (20). In summary, the expression levels of ICAM-1, VCAM-1 and α₅β₃ integrin appear to correlate with the level of tumor cell adhesion to HMCs in vitro and tumor growth in vivo. Down-regulation of these adhesion molecules would therefore be a promising target to reduce abdominal inoculation of cancer cells.

One potential agent for preventing peritoneal adhesion is simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. Simvastatin belongs to the lipophilic statins, achieving higher levels of exposure in non-hepatic tissues, while hydrophilic statins are primary hepatoselective (21). Besides its use as a lipid-reducing drug, further evidence suggests that systemic statin use could extend to prevention and treatment of different cancers (22,23). Statins have been found in an in vivo model of peritoneal carcinomatosis. One potential agent for preventing peritoneal adhesion is simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. Simvastatin belongs to the lipophilic statins, achieving higher levels of exposure in non-hepatic tissues, while hydrophilic statins are primary hepatoselective (21). Besides its use as a lipid-reducing drug, further evidence suggests that systemic statin use could extend to prevention and treatment of different cancers (22,23). Statins have been found in an in vivo model of peritoneal carcinomatosis.

Materials and methods

Materials. Medium 199 (M199), type II collagenase and CellTrace CFSE Cell Proliferation Kit were obtained from Invitrogen (Carlsbad, CA). Heparin sodium was supplied by Ratiopharm (Ulm, Germany). Iscove’s modified Dulbecco’s medium (IMDM) was from Lonza (Basel, Switzerland); human serum (HS) and endothelial cell growth supplement (ECGS) from PromoCell (Heidelberg, Germany). Fibronectin, propidium iodide (PI) and PKH67 Cell Linker Kit were supplied by Sigma-Aldrich (St. Louis, MO). Formaldehyde solution, fetal calf serum (FCS), accutase, penicillin/streptomycin solution and bovine serum albumin (BSA) were purchased from Fluka (Buchs, Switzerland), PAAS Laboratories (Pasching, Austria) and Carl Roth (Karlsruhe, Germany), respectively. Simvastatin and dimethyl sulfoxide (DMSO) were from Calbiochem/Merck (Darmstadt, Germany). Simvastatin was dissolved in DMSO and stored as stock solutions of ≥103 M at -20°C. The final concentrations of DMSO did not exceed 0.01% (vol/vol). The following anti-human antibodies (unless otherwise indicated) were obtained from Abcam (Cambridge, UK): fluorosecin isothiocyanate (FITC)-conjugated anti-mouse cytokeratin 18 IgG1 (clone DC10), phycoerythrin (PE)-labeled donkey polyclonal to rabbit IgG, rabbit IgG isotype control and rabbit polyclonal to glyceraldehyde 3-phosphate dehydrogenase (GAPDH); for adhesion-blocking experiments, monoclonal anti-ICAM-1 (clone B-H17), anti-VCAM-1 (clone B-K9) and anti-α₅-integrin (clone HP2/7). Further anti-human VCAM-1 IgG1 (clone STA, PE-labeled), anti-human ICAM-1 IgG2a (clone MEM-11, FITC-labeled) and the isotype controls mouse IgG2a (clone MOPC-173, FITC-labeled) and mouse IgG1 (clones MO-P2-21, PE-labeled; MG1-45, purified) were obtained from BioLegend (San Diego, CA). Cytofix/Perm, Perm/Wash and mouse anti-human β₅-integrin IgG1 (CD29; clone MAR4, PE-labeled) were from BD Biosciences (Heidelberg, Germany). The monoclonal antibodies against human integrin α₅-chain (α₅β₃); clone Y9A2 and the integrin β₅-chain (CD29; clone 4B4) were purchased from Abd Serotec (Raleigh, NC) and Beckman Coulter (Brea, CA), respectively. Recombinant human VCAM-1 and tumor necrosis factor (TNF) were from R&D Systems (Wiesbaden, Germany) and PeproTech (Hamburg, Germany), respectively.

Cell isolation and culture. HMCs were isolated from the greater omentum by enzymatic digestion with collagenase. HMCs were isolated from the greater omentum by enzymatic digestion with collagenase. This method was approved by the ethics committee of the Faculty of Medicine and University Hospital at the University of Tübingen, Germany. The isolation procedure was based on the method described by Stylianou et al (27). After enzymatic disaggregation, HMCs were grown on fibronectin-coated dishes in nutrition medium containing M199 supplemented with 20 mmol/l HEPES (pH 7.4), 2 mmol/l glucose, 5% HS, 15% FCS, ECGS (150 μg/ml), 5 IU/ml hirudin, penicillin (100 IU/ml), and streptomycin (100 μg/ml). HMCs were assessed by uniform cobblestone appearance at confluence, with transmitted-light microscopy. Additionally, they were tested as positive for cytokeratin 18 using flow cytometry (data not shown). For the experiments, cells were incubated with nutrient-deficient medium without growth factor. HMCs from the same isolation of one donor were partly pre-incubated with 10 ng/ml TNF for 15 h, mimicking inflammatory conditions, as mentioned in the results. Unstimulated and inflammatory conditions were tested in pairwise fashion with HMCs derived from the same individuals.

SKOV-3, OvCar-29, OAW42 and FraWü tumor cells were derived from ovarian cancer and HT29 cells from colorectal cancer. SKOV-3, OvCar-29 (subclone of OvCar-3) and HT29 were purchased from the American Type Culture Collection (ATCC; HTB-77, HTB 161 and HTB-38, respectively). OAW42 was from the European Collection of Cell Cultures (ECACC; 85073102). The cell line FraWü was derived from a malignant ascites effusion of an ovarian cancer patient and established in our laboratory. FraWü was authenticated by expression of different cancer/testis antigens (e.g., MAGE-1,3,4) and overexpression of self antigens (e.g., HER-2/neu) (28). They were cultured in IMDM with 10% FCS, penicillin (100 IU/ml), and streptomycin (100 μg/ml). During the experiments, the cells were incubated with nutrient-deficient HMC culture medium, which did not affect cell survival. For all adhesion assays, the vitality of tumor cells was ≥95% after dyeing, which was quantified by trypan-blue staining.
Flow cytometry analysis. The effect of simvastatin on the expression of VCAM-1, β1 integrin chain and ICAM-1 on HMCs and tumor cells was assessed using flow cytometry. They were treated with simvastatin for 24-72 h at concentrations varying from 0.01 to 100 µM. DMSO and medium served as controls. All cells were removed from the 24-well culture dish with accutase, as this mild treatment hardly affects cell surface molecule expression. For extracellular staining, they were incubated with anti-VCAM-1, anti-ICAM-1 and anti-β1 integrin chain fluorescence-labeled antibodies or isotype controls at 4°C for 20 min. For intracellular staining of cytokeratin 18 and GAPDH, the cells were permeabilized with 100 µl of Cytofix/Perm solution for 20 min at 4°C. Perm/Wash buffer was used for subsequent staining steps. For primary antibody staining, rabbit polyclonal to GAPDH or rabbit IgG, as isotype control, were incubated for 30 min at 4°C. Staining with the secondary antibody, donkey polyclonal to rabbit IgG, was performed similarly. PI staining was used to analyze cell viability during simvastatin treatment. All cell suspensions were examined using the FACS Calibur cytometer (BD Biosciences). The data were analyzed on the basis of mean fluorescence intensity (MFI) using CellQuest Pro software.

Fluorescence reader analysis. HMC monolayers were grown to confluence on 24-well culture dish. As adhesion molecule down-regulation by simvastatin reached its maximum at 10 µM after 48 h, adhesion assays were performed under these conditions. Incubation with medium and DMSO served as controls. All blocking experiments were performed at a concentration of 5 µg/ml of blocking antibody. The reduction in tumor cell adhesion to HMCs was at its maximum at this concentration (data not shown). The blocking antibodies were added 30 min before tumor cells were applied to the HMC monolayers. Incubation was carried out in presence of the antibodies. CFSE staining of tumor cells followed the instructions of the manufacturer (Invitrogen). Cells (10⁶) were stained with a final CFSE concentration of 7.5 µM. Tumor cells (10⁵) were added to the confluent HMCs corresponding to a tumor cell-HMC ratio of 1:1. After incubation for 48 h, each well was washed three times with PBS and fixed in 1% formaldehyde/PBS. The plates were measured directly using a Wallac 1420 Victor Multilabel Counter (Perkin-Elmer, USA). The arbitrary fluorescence units (AFU) corresponded to the number of adherent tumor cells.

Cell adhesion assay. Specific cell adhesion to recombinant VCAM-1 was performed as previously described by Klein et al (29). Briefly, 0.75 µl of 0.5 µg/µl VCAM-1 stock solution was spotted on plastic dishes and immobilized by air-drying. Non-specific binding to plastic dish was prevented by 90 min pre-incubation with 1% BSA/PBS. SKOV-3 cells were added for 20 min, partly pre-incubated with 5 µg/ml blocking antibodies for 30 min. Non-adherent cells were removed by gently washing with pre-warmed PBS. Adhesion was evaluated under a Zeiss Axioplan2 microscope. Photographs of representative fields were taken.

Statistical analyses. Fluorescence reader and flow cytometry experiments were conducted at least 3-fold in triplicate. HMCs always derived from three different individuals. The experimental group was analyzed using the t-test, except for antibody blocking experiments (Mann-Whitney rank sum test). Findings were considered statistically significant at either *P≤0.05, **P≤0.01 or ***P≤0.001.

Results

Simvastatin reduces expression of VCAM-1 on HMCs and ICAM-1 on SKOV-3 cells. Maximum down-regulation of VCAM-1 expression on HMCs was observed with 10 µM simvastatin after 48 h (Fig. 1A). Overall, in unstimulated conditions, the reduction averaged 41.17±16.7 and 34.11±11.42% after TNF pre-incubation, compared to DMSO controls. The effect was significant for 10 and 100 µM (Pz0.01). The total expression of VCAM-1 was increased by TNF administration. Considering individual basic VCAM-1 levels, the overall mean increase was 27.96±19.12%. In opposite to VCAM-1, ICAM-1 surface expression after simvastatin (Simva) incubation on HMCs. TNF represents inflammatory conditions in contrast to unstimulated HMCs. Isotype controls did not exceed MFI of 5 for GAPDH or MFI of 10 for ICAM-1/VCAM-1 staining. (C), ICAM-1 expression on SKOV-3 cells. The graphs represent one out of three triplicate stainings. Significance refers to medium and DMSO controls. The data represent means ± standard deviation.
DMSO control to a similar extent after TNF incubation. An adverse effect was detected for the tumor cells. SKOV-3 survival was reduced by 10 µM simvastatin by 11.49±1.44% in average compared to controls. Similar results were achieved for OvCar-29, FraWü and OAW42 cells.

The ICAM-1 level on SKOV-3 cells was significantly reduced under simvastatin treatment (P≤0.001), (Fig. 1C). The maximum decrease was achieved with 10 µM simvastatin after 48 h. ICAM-1 expression was lowered to ~60%. SKOV-3 cells only express minimal levels of VCAM-1, which did not underlie any significant changes during simvastatin treatment (data not shown).

Simvastatin reduces adhesion molecule expression for at least 48 h. Kinetic analyses were carried out at 10 µM as simvastatin achieved its maximum effect at this concentration (Fig. 1). The reduction of VCAM-1 expression started about 24 h after incubation, became significant after 48 h and lasted up to 72 h (P≤0.01) (Fig. 2A). No effects were detectable before 24 h. The same was true for ICAM-1 down-regulation on SKOV-3 cells (data not shown). By contrast, a significant decrease in ICAM-1 expression on HMCs (Fig. 2B) was not detected over time. Evaluation was not carried out at longer culture periods to exclude cellular exhaustion due to omission of medium exchanges.

VCAM-1, α₄ and β₁ integrin chain blockade reduces SKOV-3 adhesion to HMCs. As confirmed for VCAM-1 and ICAM-1 on HMCs in this study (Fig. 1) the expression of adhesion molecules is up-regulated by inflammatory stimuli such as TNF (22,30). The effect of inhibitory antibodies and simvastatin (see below) was therefore examined under unstimulated conditions in comparison with TNF pre-incubation of HMCs. Under unstimulated conditions, antibody-mediated VCAM-1 blocking reduced SKOV-3 adhesion to HMCs by 30.42±12.40%, which was even about 10% higher under inflammatory conditions (Fig. 3A). The decrease in adherence in comparison with the control medium was significant (P≤0.01/0.001). ICAM-1 blocking did not show any effect on SKOV-3 alone, nor did it have any additive effect in combination with VCAM-1 blocking. TNF pre-incubation of HMCs resulted in 15.76±11.04% increase of adherent SKOV-3 cells in medium controls.

VCAM-1, α₄ and β₁ integrin chain blockade reduces SKOV-3 adhesion to HMCs. As confirmed for VCAM-1 and ICAM-1 on HMCs in this study (Fig. 1) the expression of adhesion molecules is up-regulated by inflammatory stimuli such as TNF (22,30). The effect of inhibitory antibodies and simvastatin (see below) was therefore examined under unstimulated conditions in comparison with TNF pre-incubation of HMCs. Under unstimulated conditions, antibody-mediated VCAM-1 blocking reduced SKOV-3 adhesion to HMCs by 30.42±12.40%, which was even about 10% higher under inflammatory conditions (Fig. 3A). The decrease in adherence in comparison with the control medium was significant (P≤0.01/0.001). ICAM-1 blocking did not show any effect on SKOV-3 alone, nor did it have any additive effect in combination with VCAM-1 blocking. TNF pre-incubation of HMCs resulted in 15.76±11.04% increase of adherent SKOV-3 cells in medium controls.
α4 integrin chains are required for VCAM-1 mediated adhesion of SKOV-3 cells (Fig. 3B). The light microscopy photographs clearly demonstrate that blocking of β1 and α4 integrin chains resulted in a dramatic inhibition of cell adhesion compared to medium and IgG controls. By contrast blocking of α9β1 integrin showed almost no effect.

Furthermore, inhibitory antibodies against the integrin α4-chain, the β1-chain and the αβ1 integrin were also tested to prevent SKOV-3 adhesion to HMCs (Fig. 3C). Blocking of α4 and β1 integrin chains resulted in a decrease in adhesion after 48 h incubation of approximately one fifth in each case under unstimulated and inflammatory conditions; however these effects were only significant for β1 integrin chain inhibition after TNF pre-incubation (P≤0.05). The effect was raised to one third and higher by combining β1 and α4 integrin chain inhibition with antibody blockade of VCAM-1 (P≤0.01). By contrast, α9β1 integrin blocking did not decrease adhesion of SKOV-3 cells to HMCs.

Simvastatin reduces ovarian cancer cell adherence to HMCs. After simvastatin incubation, SKOV-3 adhesion was significantly reduced to approximately one third in comparison with DMSO controls in unstimulated conditions and after TNF stimulation (P≤0.001) (Fig. 4A). Simvastatin also reduced adhesion of the ovarian cancer cell lines FraWü (Fig. 4B), OvCar-29 (Fig. 4C) and OAW42 (Fig. 4D). FraWü was the only cell line which showed a considerable increase of adhesion under DMSO compared to medium. Nevertheless, simvastatin lowered FraWü adhesion to HMCs to <50% under both conditions. OvCar-29 cell adhesion was reduced by 35% under unstimulated conditions and the effect was almost doubled to 70% reduction after TNF pre-incubation (P≤0.001). With OAW42 cells the decrease of adhesion was ~27% (unstimulated) and 45% (inflammatory conditions).

Simvastatin reduces β1 integrin chain expression on ovarian cancer cells and HMCs. Inhibition of the β1 integrin chain was the most effective one in reducing SKOV-3 adhesion to its ligand VCAM-1 and to HMCs. Therefore β1 integrin chain expression on ovarian cancer cells was analyzed under simvastatin treatment (Fig. 5A). Simvastatin reduced the β1 integrin chain expression significantly on all ovarian cancer cells (P≤0.01). It reached its maximum at 10 µM after 48-h incubation. The highest effect was achieved with OvCar-29 cells. β1 integrin chain expression was reduced to <50% compared to controls (P≤0.001). Further 10 µM simvastatin also reduced β1 integrin chain expression on HMCs about one third under inflammatory and unstimulated condition (Fig. 5B); however this effect was only significant after TNF pre-incubation (P≤0.05).

Simvastatin does not influence ICAM-1 expression on HT29 cells. Simvastatin did not significantly reduce ICAM-1 expression on HT29 cells at any dosages after 48 h (Fig. 6A) or during kinetic analyses (data not shown). VCAM-1 was not expressed on HT29 cells (data not shown). PI-staining proved that survival of HT29 cells was slightly decreased by 7.16±6.94% under simvastatin treatment compared to controls (data not shown).
HT29 adhesion to HMCs is reduced by ICAM-1 inhibition and simvastatin treatment. HT29 cell adherence to HMCs was only decreased by ICAM-1 blocking (Fig. 6B). In unstimulated conditions, ICAM-1 inhibition reduced HT29 adhesion by 26.26±4.22%, which was elevated about 10% after TNF pre-incubation. Comparing medium controls, under inflammatory conditions total adhesion of HT29 was increased about one third. VCAM-1 inhibition did not show an effect alone nor in combination with ICAM-1.

Simvastatin only reduced adhesion of HT29 cells to HMCs to ~50% under unstimulated conditions (P≤0.001), (Fig. 6C). By contrast, after TNF pre-incubation simvastatin did not decrease HT29 adhesion compared to DMSO.

Discussion

The data reported here uncover simvastatin as a promising agent for preventing cancer cell adhesion to HMCs. For this purpose the reduction of VCAM-1 and α4β1 integrin expression by simvastatin has to be considered as major molecular mechanism. This may provide a new possibility to prevent intra-abdominal tumor cell adhesion and peritoneal carcinomatosis.

Microscopic intra-peritoneal tumor lesions often elude surgical treatment (13). They are regarded as one cause of peritoneal carcinomatosis (12-14). Cancer cell dissociation
from the primary tumor or their exfoliation during surgery are the first steps of peritoneal carcinomatosis (12,13,31). Besides intraoperative cytotoxic strategies, a promising method to avoid intra-peritoneal inoculation seems to be the inhibition of cancer cell adhesion to HMCs (17,19).

The adhesion molecules VCAM-1, ICAM-1 and members of the \( \beta_1 \) integrin subfamily appear to be promising targets to reduce intra-abdominal metastasis. Simvastatin reduced the level of VCAM-1 expression on HMCs and \( \beta_1 \) integrin chain levels on ovarian cancer cells and HMCs significantly. VCAM-1, \( \alpha_4 \) and \( \beta_1 \) integrin chains blocking decreased adherence of SKOV-3 cells to HMCs. Adhesion of SKOV-3 to HMCs was also substantially reduced by simvastatin to one third. This also accounts to similar extent for all further tested ovarian cancer cell lines. These observations provide proof-of-principle evidence that simvastatin decreases SKOV-3 adhesion to HMCs via VCAM-1 down-regulation on HMCs and reduced expression of its ligand \( \alpha_4 \beta_1 \), integrin on the ovarian cancer cells tested. Further ICAM-1 expression on SKOV-3 cells also declined during simvastatin treatment; however ICAM-1 blockade could not prevent SKOV-3 adhesion to HMCs. Therefore, it is unlikely that it is involved in decreased SKOV-3 adhesion to HMCs.

Interestingly, simvastatin reduced the adhesion of HT29 colorectal tumor cells to HMCs only under unstimulated conditions but not after TNF pre-incubation. Furthermore, HT29 adhesion to HMCs was reduced by ICAM-1 blocking. ICAM-1 expression on HMCs has been described to play a central role in the adhesion process of HT29 (19,32). LFA (lymphocyte function-associated antigen)-1 is a member of the \( \beta_2 \) integrin subfamily and a ligand of ICAM-1. It is expressed on the surface of HT29 cells (32,33). Despite this, simvastatin had no effect on ICAM-1 expression, either on HMCs or on HT29 cells. The influence of simvastin on HT29 adhesion to HMCs thus appears to be independent of ICAM-1 expression.

Adhesion molecule blocking antibodies have successfully been used to decrease tumor cell-host cell interactions and consequently reduced tumor metastasis in vivo (17,19,20). Therefore, they are regarded as promising targets for therapeutic intervention (17,19,20). Nevertheless, intercellular adhesion requires different adhesion molecules at the same time (17,33,34). In contrast to inhibitory antibodies, which only target one defined adhesion molecule, simvastatin lowered different adhesion molecules on ovarian cancer cells and HMCs contemporaneously. This explains that simvastatin could reduce SKOV-3 adhesion to HMCs to one third although antibody blocking of VCAM-1 and/or \( \beta_1 \) integrin only resulted in a 40% maximum decrease. Nevertheless simvastatin does not generally lower surface molecule expression but rather seems to reduce selective molecules. ICAM-1 expression on HMCs stayed unchanged; however, VCAM-1 was clearly down-regulated.

Certain statins, including simvastatin, induce cell death in ovarian cancer cells in vitro (35-37). Therefore, PI staining was performed to exclude that the decreased numbers of adherent tumor cells by simvastatin were only due to cell death induction. The survival of ovarian cancer cells and HT29 was indeed slightly lowered. Nevertheless about 10% reduced vitality could not account for 30-70% less tumor cell adhesion alone. Consequently the reduction of tumor cell adhesion to HMCs by simvastatin seemed to be primarily due to a decreased surface expression of adhesion molecules.

Physical stress, for example by surgery, or chemical injury to the peritoneum, provokes a sterile local inflammation, which is a privileged site of tumor recurrence (10,16,38,39). The up-regulation of adhesion molecules on HMCs is regarded as causal mechanism behind this observance (30,40). Simvastatin decreased ovarian cancer cell adherence to HMCs under unstimulated and TNF pre-incubated conditions. This finding underlines that it may be a promising substance for intra-abdominal application after surgery to prevent the adhesion of tumor cells to HMCs. Further, simvastatin did not impinge upon the vitality or the metabolism of HMCs after 48-72 h treatment. Equal GAPDH levels in controls and under simvastatin proved that down-regulation of adhesion molecules on HMCs was not due to general inhibition of cell metabolism. Therefore it seems improbable that simvastatin would cause additional inflammatory stress to the HMC monolayer in vivo. In addition, the long-lasting effect of simvastatin of at least 48 h emphasizes potential benefits in peri-operative settings.

The use of statins for cardiovascular indications and a coeval reduction of cancer incidence has been reported (22,23). In a retrospective study, statins improved overall survival in patients with epithelial ovarian cancer (41). By contrast, a recent retrospective cohort study failed to show a correlation between statin use and reduced ovarian cancer incidence (42). Results are also inconsistent for colorectal cancer. In a case-control study including 1953 cancer patients and 2015 controls, the use of statins was associated with 47% relative reduction in the risk of colorectal cancer (43). Nevertheless, a systematic review of 42 randomized trials states that statins have protective effects on only certain cancers like stomach, liver and lymphoma but not on colorectal cancer (44). To date little is known about the molecular mechanisms of simvastatin, which are responsible for its anti-cancer effects. The current findings suggest that down-regulation of adhesion molecules, especially of VCAM-1 and \( \beta_1 \) integrin chain may be involved, however this still has to be proven for systemic application. As simvastatin decreased ovarian cancer and HT29 tumor cell adhesion to HMCs significantly, besides systemic use, direct local application of simvastatin may be considered as a promising option to prevent intra-peritoneal cancer cell adhesion.

Overall, as an example of adhesion molecule down-regulating drugs in general, simvastatin may be a promising agent for preventing peritoneal carcinomatosis. Since we found the effect on several ovarian cancer cell lines, simvastatin treatment might warrant evaluation in patients with ovarian cancer, in particular in VCAM-1 and \( \alpha_4 \beta_1 \) integrin-dependent tumor metastasis.

Acknowledgments

We thank Tobias Feuchtinger and Amelie Halder (Department of Pediatrics, University of Tübingen, Germany) for technical support with fluorescence reader analysis and Bettina Hasslinger-Löffler and Michaela Brück (Institute of Microbiology, University of Münster, Germany) for sharing their expertise in working with HMCs. Further grant support was provided by fortüne-funding (1793-0-1), Medical Faculty, University of Tübingen, Germany (B. Wagner) and by the Deutsche Forschungsgemeinschaft grant SFB 685/Z3, Department of Immunology, University of Tübingen, Germany (B. Wagner, S. Löb).
References


